Contract awarded under the BARDA DRIVe (Division of Research, Innovation, and Ventures) initiative to harness a patient’s systemic response to inform on health threats and clinical impact
TIRAT CARMEL, Israel; BOSTON, MA – 24 October, 2023 – MeMed, a leader in host response technologies, is pleased to announce that it has been awarded a contract valued at $727,799 by the Division of Research, Innovation, and Ventures (DRIVe) of the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA). The contract will support the execution of a randomized controlled trial designed to build on existing clinical utility data demonstrating that MeMed BV can improve patient outcomes.
The FDA-cleared MeMed BV test is a pioneering host response-based diagnostic tool. Within just 15 minutes, it accurately distinguishes between bacterial and viral infections across multiple healthcare settings, supporting appropriate antibiotic use and thereby helping to combat antibiotic resistance − one of the biggest threats to global health.
Eran Eden, CEO of MeMed, said: “We are committed to generating the highest level of clinical utility evidence to establish the impact of MeMed BV on improving patient outcomes. We are delighted to have BARDA as a partner in this endeavour. Together with the cumulating real-world data from sites using MeMed BV today, the trial results will contribute to making MeMed BV the standard of care.”
“We’re hugely grateful to BARDA for its recognition of the value that host-based diagnostics bring to clinical decision-making and improved patient outcomes alongside bolstering the nation’s response to national health emergencies. This contract follows U.S. Department of Defense funding that supported development of MeMed Key, a platform to rapidly measure MeMed BV that will be employed in the trial,” commented Tanya Gottlieb, VP Scientific Affairs at MeMed.
This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C0004.
About MeMed
At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. By leveraging expertise in host-response profiling and machine-learning algorithms, MeMed is creating a portfolio of tests that address tough clinical dilemmas.
Follow and connect with MeMed via LinkedIn, Twitter, and Facebook.
MeMed Contacts:
Tanya Gottlieb, VP Scientific Affairs, MeMed
[email protected]
Media relations contact:
ICR Consilium
Attachment
GlobeNewswire Distribution ID 1000885606